Further supporting an active role for CB2, HU308 (15 mg/kg i.p. daily, starting after observation of robust MS-related symptoms) reduced symptoms and associated inflammatory markers, with no such effect in CB2 KO animals [179]. This evidence concerns the gene CNR2 and myeloid sarcoma.